📋 PubMed 週次論文ダイジェスト

2026-11-13 (Fri)  |  検索期間: 2026-11-11 〜 2026-11-13

計 9 件 小児・AYA血液腫瘍 免疫療法(小児・AYA) 小児固形がん MRD(年齢不問) がんゲノミクス(年齢不問) 造血幹細胞(年齢不問) がん幹細胞(年齢不問) AML・MDS(年齢不問)
Clinical Paper Readerで読む →
Nat Commun
Interpretable and scalable spatial gene set activity analysis with GESSO uncovers functional tissue architecture.
Nat Commun. 2026 Oct 14;17(1).
Abstract
Spatially resolved transcriptomics (SRT) measures gene expression within tissues. Existing methods that summarize the activity of functionally related genes often ignore relationships between neighboring locations and offer limited statistical testing, gene-level interpretation, or scalability.…
Blood
Clinical and genomic convergence of high-risk CCUS and lower-risk myelodysplastic syndromes/neoplasms.
Blood. 2026 Nov 12;148(20):2528-2539.
Abstract
Clonal cytopenia of undetermined significance (CCUS) is defined by unexplained cytopenias with myeloid-associated somatic mutations not meeting the diagnostic criteria for myelodysplastic syndromes/neoplasms (MDS), yet it carries a highly risk-stratified probability of progression to myeloid…
Blood
Functional restoration of immune defects in STAT1 gain-of-function disease after stem cell gene editing.
Blood. 2026 Nov 12;148(20):2497-2510.
Abstract
Germ line gain-of-function (GOF) mutations in the signal transducer and activator of transcription 1 (STAT1) gene cause a dominantly inherited inborn error of immunity (IEI) characterized by chronic mucocutaneous candidiasis, autoimmunity, severe opportunistic infections, and an increased risk of…
Leukemia
Mediator kinase inhibition exposes a transcriptional vulnerability and synergizes with venetoclax in AML.
Leukemia. 2026 Nov 11.
Abstract
Acute myeloid leukemia (AML) is a heterogeneous and aggressive hematologic malignancy associated with poor survival despite recent therapeutic advances. To identify novel anti-leukemic agents, we performed a high-throughput viability screen of 10,000 small molecules across 56 genetically diverse…
Haematologica
Response to Comment on: "Avatrombopag as a novel salvage therapy for refractory thrombocytopenia in THPO-mutated congenital amegakaryocytic thrombocytopenia after allogeneic hematopoietic stem cell transplantation".
Haematologica. 2026 Nov 12.
アブストラクト未収載
Haematologica
Functional DNase assessment in posttransplant lung injury. Comment on: "Neutrophil extracellular traps and DNase I levels in the bronchoalveolar lavage fluid of children with pulmonary injury after allogeneic hematopoietic stem cell transplantation: a TRANSPIRE study".
Haematologica. 2026 Nov 12.
アブストラクト未収載
Haematologica
Teclistamab in multiple myeloma with coexisting myelodysplastic syndrome or acute myeloid leukemia.
Haematologica. 2026 Nov 12.
アブストラクト未収載
Int J Hematol
Clinical spectrum and hematopoietic stem cell transplantation outcomes in Japanese patients with GATA2 deficiency.
Int J Hematol. 2026 Nov 11.
Abstract
GATA2 deficiency is an inherited bone marrow failure and immunodeficiency syndrome with diverse infectious, hematologic, and systemic manifestations. Although well characterized in Western populations, its clinical phenotype in Japan remains insufficiently defined. We conducted a nationwide…
Exp Hematol
Dismantling the immune-metabolic barrier in TP53-mutant hematologic malignancies.
Exp Hematol Oncol. 2026 Nov 11;15(1).
Abstract
Tumor protein 53 (TP53) mutations, long recognized as harbingers of poor prognosis, drive treatment failure in hematologic malignancies by erecting two mutually reinforcing defense systems. Immune evasion is effected through silencing of death-receptor signaling, crippled antigen presentation, and…
Obsidian / Notion にそのままペーストできます